135 related articles for article (PubMed ID: 10647876)
1. The role of interferon-alpha in the treatment of idiopathic myelofibrosis.
Bachleitner-Hofmann T; Gisslinger H
Ann Hematol; 1999 Dec; 78(12):533-8. PubMed ID: 10647876
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic myelofibrosis: pathogenesis, natural history and management.
Reilly JT
Blood Rev; 1997 Dec; 11(4):233-42. PubMed ID: 9481452
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.
Hasselbalch HC; Bjerrum OW; Jensen BA; Clausen NT; Hansen PB; Birgens H; Therkildsen MH; Ralfkiaer E
Am J Hematol; 2003 Dec; 74(4):238-42. PubMed ID: 14635203
[TBL] [Abstract][Full Text] [Related]
4. Idiopathic myelofibrosis.
Barosi G; Hoffman R
Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
[TBL] [Abstract][Full Text] [Related]
5. Idiopathic myelofibrosis--an update with particular reference to clinical aspects and prognosis.
Hasselbalch HC
Int J Clin Lab Res; 1993; 23(3):124-38. PubMed ID: 8400333
[TBL] [Abstract][Full Text] [Related]
6. Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study.
Heis-Vahidi-Fard N; Forberg E; Eichinger S; Chott A; Lechner K; Gisslinger H
Ann Hematol; 2001 Feb; 80(2):79-82. PubMed ID: 11261329
[TBL] [Abstract][Full Text] [Related]
7. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study.
Thiele J; Kvasnicka HM; Boeltken B; Zankovich R; Diehl V; Fischer R
Leukemia; 1999 Nov; 13(11):1741-8. PubMed ID: 10557047
[TBL] [Abstract][Full Text] [Related]
8. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC;
Pathol Biol (Paris); 2001 Mar; 49(2):153-7. PubMed ID: 11317961
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
10. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Ann Hematol; 2001 Mar; 80(3):160-5. PubMed ID: 11320901
[TBL] [Abstract][Full Text] [Related]
11. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
Dalley A; Smith JM; Reilly JT; Neil SM
Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
[TBL] [Abstract][Full Text] [Related]
12. Early-stage idiopathic (primary) myelofibrosis--current issues of diagnostic features.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Leuk Lymphoma; 2002 May; 43(5):1035-41. PubMed ID: 12148883
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Schmitt-Gräff A; Hülsemann R; Diehl V
Histol Histopathol; 2004 Jan; 19(1):239-50. PubMed ID: 14702192
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Diehl V
Histopathology; 2003 Nov; 43(5):470-9. PubMed ID: 14636273
[TBL] [Abstract][Full Text] [Related]
15. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta.
Rameshwar P; Denny TN; Stein D; Gascón P
J Immunol; 1994 Sep; 153(6):2819-30. PubMed ID: 7521370
[TBL] [Abstract][Full Text] [Related]
16. Peripheral T cell lymphoma, not otherwise specified with myelofibrosis: report of a case with review of the literature.
Sekiguchi Y; Shirane S; Shimada A; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2015; 8(4):4186-203. PubMed ID: 26097612
[TBL] [Abstract][Full Text] [Related]
17. Biology and management of idiopathic myelofibrosis.
Smith BD; Moliterno AR
Curr Opin Oncol; 2001 Mar; 13(2):91-4. PubMed ID: 11224705
[TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and management of idiopathic myelofibrosis.
Reilly JT
Baillieres Clin Haematol; 1998 Dec; 11(4):751-67. PubMed ID: 10640215
[TBL] [Abstract][Full Text] [Related]
19. Systemic transforming growth factor-beta in patients with bone marrow fibrosis--pathophysiological implications.
Rameshwar P; Chang VT; Thacker UF; Gascón P
Am J Hematol; 1998 Oct; 59(2):133-42. PubMed ID: 9766798
[TBL] [Abstract][Full Text] [Related]
20. SU6668 in idiopathic myelofibrosis--a rational therapeutic approach targeting several tyrosine kinases of importance for the myeloproliferation and the development of bone marrow fibrosis and angiogenesis.
Hasselbalch HC
Med Hypotheses; 2003 Aug; 61(2):244-7. PubMed ID: 12888313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
